Patents by Inventor Michael G. Brattain

Michael G. Brattain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer diagnosis and therapy based on mutations in TGF-beta receptors
    Publication number: 20040038284
    Abstract: This invention is based on the discovery that the type II TGF&bgr; receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
    Type: Application
    Filed: August 21, 2003
    Publication date: February 26, 2004
    Applicants: Case Western Reserve University, Medical College of Ohio
    Inventors: Sanford D. Markowitz, Michael G. Brattain, James K. V. Willson
  • Cancer diagnosis and therapy based on mutations in TGF-&bgr; receptors
    Patent number: 6630326
    Abstract: This invention is based on the discovery that the type II TGF&bgr; receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: October 7, 2003
    Assignees: Case Western Reserve University, Medical College of Ohio
    Inventors: Sanford D. Markowitz, Michael G. Brattain, James K. V. Willson
  • Cancer diagnosis and therapy based on mutations in TGF-beta receptors
    Publication number: 20020064786
    Abstract: This invention is based on the discovery that the type II TGF&bgr; receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
    Type: Application
    Filed: June 13, 2001
    Publication date: May 30, 2002
    Inventors: Sanford D. Markowitz, Michael G. Brattain, James K. V. Willson
  • Cancer diagnosis and therapy based on mutations in TGF-&bgr; receptors
    Patent number: 6291237
    Abstract: This invention is based on the discovery that the type II TGF&bgr; receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: September 18, 2001
    Assignees: Case Western Reserve University, Medical College of Ohio
    Inventors: Sanford D. Markowitz, Michael G. Brattain, James K. V. Willson
  • Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor .beta. and homologous growth controlling factors
    Patent number: 5866323
    Abstract: This invention is based on the discovery that the type II TGF-.beta. receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: February 2, 1999
    Assignees: Case Western Reserve University, Medical College of Ohio
    Inventors: Sanford D. Markowitz, Michael G. Brattain, James K. V. Willson